Article citationsMore>>

T. Opriessnig, A. R. Patterson, D. M. Madson, N. Pal and P. G. Halbur, “Comparison of Efficacy of Commercial One Dose and Two Dose PCV2 Vaccines Using a Mixed PRRSV-PCV2-SIV Clinical Infection Model 2-3-Months Post Vaccination,” Vaccine, Vol. 27, No. 7, 2009, pp. 1002-1007. doi:10.1016/j.vaccine.2008.11.105

has been cited by the following article:

• TITLE: Porcine Circovirus 2: Immunopathogenesis and Recent Developments in Vaccines

  AUTHORS: Abelardo Silva Júnior, Otávio Valério de Carvalho, Luiz Henrique Silva Bulos, Juliana Lopes Rangel Fietto, Mauro Pires Moraes, Márcia Rogéria de Almeida

  KEYWORDS: Porcine circovirus 2; Vaccine; Immunopathogenesis

  JOURNAL NAME: World Journal of Vaccines, Vol.2 No.2, May 24, 2012

  ABSTRACT: Porcine circovirus 2 (PCV2) is currently considered an important etiologic agent of swine and its infection has potentially serious economic impact on the swine industry worldwide. This virus is frequently associated with postweaning multisystemic wasting syndrome (PMWS), and also with other clinical conditions such as porcine dermatitis and nephropathy syndrome (PDNS), late-term abortions, reproductive failure in sows, proliferative and necrotizing pneumonia and congenital tremors. The term porcine circovirus-associated disease (PCVAD) is currently used to refer to any of these diseases when they are associated with PCV2 infection. The PCV2 was recognized as a pathogen in 1997, and many questions regarding its biology and pathogenesis remain unanswered. Currently, some studies have shown the production of new vaccine candidates and field efficacy testing of commercial vaccines. This review discusses some major points concerned with immunopathogenesis and vaccines for PCV2 infection.